Keyphrases
Chemotherapy
100%
Should Be Given
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Androgen Deprivation Therapy
100%
Docetaxel
50%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
50%
Overall Survival
25%
Disease Burden
25%
Effective Therapy
25%
Long Follow-up
25%
Phase III Clinical Trial
25%
Antitumor Effect
25%
Disease Course
25%
Androgens
25%
Clinical Benefit
25%
Cytotoxic Chemotherapy
25%
High Response Rate
25%
Therapy Outcome
25%
Cytotoxic Therapy
25%
Castration-resistant
25%
Incurable Disease
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Chemotherapy
100%
Androgen
83%
Diseases
66%
Cytotoxic Chemotherapy
33%
Docetaxel
33%
Clinical Trial
16%
Overall Survival
16%
Disease Course
16%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Deprivation Therapy
66%
Diseases
50%
Cytotoxic Chemotherapy
33%
Docetaxel
33%
Clinical Trial
16%
Overall Survival
16%
Disease Burden
16%
Disease Course
16%
Androgen
16%
Nursing and Health Professions
Prostate Cancer
100%
Androgen Deprivation Therapy
66%
Diseases
50%
Docetaxel
33%
Overall Survival
16%
Disease Burden
16%
Treatment Outcome
16%
Androgen
16%
Disease Course
16%
Neuroscience
Androgen
100%
Prostate
100%
Docetaxel
40%